HDAC2 and breast carcinoma: Accumulating evidence reveals that HDAC2 facilitates cancer progression in various malignancies, including colorectal cancer [15], hepatocellular carcinoma [31], and breast cancer [32], by coordinating mechanisms such as epigenetic regulation [33], translational activation [34], and immune evasion [35], making it as a critical prognostic marker and therapeutic target.